deltatrials
Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm NCT07349641

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

Tirzepatide With Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer in Overweight and Obese Women

Sponsor: National Cancer Institute (NCI)

Conditions Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
Interventions Medical Device Usage and Evaluation Tirzepatide
Updated 2 times since 2026 Last updated: Mar 12, 2026 Started: Jul 6, 2026 Primary completion: Dec 31, 2028 Completion: Dec 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia and FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, this trial is actively recruiting participants. The trial is conducted by National Cancer Institute (NCI) and has accumulated 2 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshotNot Yet Recruiting~Mar 2026 – present · 4 months · monthly snapshotNot Yet Recruiting

Change History

2 versions recorded

  1. Mar 2026 — Present [monthly]

    Not Yet Recruiting PHASE2

  2. Feb 2026 — Mar 2026 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations